You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

56 Results
Guidelines and Advice
Jun 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
May 2025
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
May 2025
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Locally Advanced Basal Cell Carcinoma
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
May 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    capivasertib - For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, based on criteria
ODB - General Benefit
    fulvestrant
Oct 2025

Pages